FDA Inspection Workflow | GMPify Training

🏛️

FDA Inspection - Managing the On-Site Regulatory Review

An FDA inspection is the agency's direct, on-site verification that a facility operates in compliance with GMP and applicable regulation. Authority for inspection comes from Section 704 of the Food, Drug, and Cosmetic Act, and FDA investigators conduct inspections per the methodology in the Investigations Operations Manual. How a site prepares for, manages, and responds during an inspection shapes both the outcome and any post-inspection regulatory action. This map details the pathway from continuous inspection readiness through opening, daily conduct, close-out, and follow-up.

FD&C Act Section 704 · 21 CFR Part 211 · FDA Investigations Operations Manual

FD&C Act 704

21 CFR Part 211

FDA IOM

Surveillance Inspection

Routine, risk-based inspection conducted on a recurring cycle independent of any specific trigger.

Trigger: Scheduled cycle

For-Cause Inspection

Triggered by a specific concern: a complaint, a recall, an adverse event pattern, or prior inspection findings.

Trigger: Specific concern

Pre-Approval Inspection

Conducted in support of a pending marketing application, verifying the facility can produce the product as filed.

Trigger: Pending application

Follow-Up / Compliance Inspection

Verifies that corrective actions from a prior inspection or warning letter have been effectively implemented.

Trigger: Prior finding

Phase 1

Pre-Inspection Preparation

1Maintain a continuous inspection-ready state

Facility, documentation, and personnel maintained in a state ready for inspection at any time, rather than prepared reactively upon notice.

21 CFR Part 211

↓

2Activate the inspection response plan

Predefined response plan activated immediately upon investigator arrival, notifying designated roles and assembling the response team.

Internal SOP

↓

3Verify credentials and document scope

Investigator's credentials verified, and the stated scope and purpose of the inspection documented before the inspection proceeds.

FDA IOM

↓

4Assemble front room and back room teams

Front room team engages directly with the investigator, while the back room team retrieves documents and prepares information under front room direction.

Internal SOP

Phase 2

Inspection Opening and Conduct

5Conduct opening meeting

Notice of Inspection, Form FDA 482, presented and reviewed, with facility leadership introduced and the inspection's stated scope confirmed.

FD&C Act Section 704

↓

6Facilitate document and interview requests

Requested documents retrieved and provided accurately and promptly, and interview requests facilitated with appropriate subject matter experts present.

FDA IOM

↓

7Log all documents and questions

Every document provided and every question asked logged in real time, creating an internal record parallel to the investigator's own notes.

Internal SOP

↓

Does the investigator identify an objectionable condition?

YES → Document and prepare response NO → Continue routine facilitation

Phase 3

Daily Wrap-Up and Response Management

8Conduct daily wrap-up meetings

End-of-day discussion with the investigator to understand observations noted so far and clarify any open items before the next day begins.

FDA IOM

↓

9Debrief the internal team

Front room and back room teams debrief internally each evening, aligning on emerging themes and preparing for the following day.

Internal SOP

↓

10Begin drafting responses in real time

Preliminary response strategy and supporting evidence gathered for potential observations while the inspection is still underway.

Internal SOP

Phase 4

Close-Out and Post-Inspection Follow-Up

11Attend the close-out meeting

Final meeting held to review all observations, with a Form FDA 483 issued if the investigator identified objectionable conditions.

FDA IOM

↓

12Submit formal written response

Written response to any Form FDA 483 submitted within 15 business days, addressing each observation with root cause and corrective action commitments.

FDA Guidance on 483 Responses

↓

13Implement and verify corrective actions

Committed corrective actions implemented on schedule and their effectiveness verified, with the full record retained for the next inspection.

21 CFR Part 211

Inspection Types (Overview)

Surveillance

Routine, unannounced inspection on a risk-based recurring cycle, covering the facility's general state of GMP compliance.

FDA IOM

For-Cause

Triggered by a specific concern such as a complaint pattern, recall, or reported adverse event, with a narrower, targeted scope.

FDA IOM

Pre-Approval Inspection

Verifies the facility can reliably manufacture the product as described in a pending marketing application.

FDA IOM

Key FDA Forms (Overview)

Form FDA 482 Notice of Inspection, presented at the start of the inspection to establish the investigator's authority to inspect.

Form FDA 483 Inspectional Observations, issued at close-out listing conditions the investigator considers objectionable.

Form FDA 484 Receipt for Samples, issued when the investigator collects physical samples during the inspection.

Establishment Inspection Report (EIR) The investigator's complete internal report, not typically shared with the firm, that documents the full inspection and its classification.

Front Room / Back Room Roles (Overview)

Front room lead Primary point of contact with the investigator, coordinating requests and managing the flow of the inspection.

Scribe / logger Records every document requested, every document provided, and every question asked throughout the inspection.

Back room team Retrieves and reviews documents before they reach the front room, and prepares subject matter experts for interviews.

Subject matter experts Answer investigator questions within their area of expertise, briefed in advance on communication expectations.

Inspection Readiness Quality Elements

Continuous Inspection Readiness Facility and documentation maintained in an audit-ready state at all times, not assembled reactively upon notice of an inspection.

Document Request Log Complete, real-time record of every document requested and provided, supporting an accurate internal account of the inspection.

Subject Matter Expert Availability Qualified personnel available and briefed to respond to investigator questions within their area without unnecessary delay.

Daily Wrap-Up Discipline End-of-day discussions held consistently to surface and clarify investigator observations before they harden into formal findings.

Real-Time Response Drafting Preliminary response strategy developed while the inspection is still underway, rather than starting from a blank page after close-out.

483 Response Timeliness Written response submitted within 15 business days, addressing each observation with root cause and a committed timeline.

CAPA Tracking Corrective actions committed in the 483 response tracked to documented, verified completion.

Post-Inspection Trend Review Observations reviewed against prior inspections to identify recurring themes requiring broader systemic correction.

Never do this

Provide a document to the investigator without first logging it and having it reviewed by the back room. Allow an untrained employee to answer investigator questions outside their expertise. Argue with or contradict the investigator's stated observations during the inspection itself. Miss the 15 business day window for the written 483 response.

482 vs 483 vs 484 vs EIR

Form 482 opens the inspection and establishes authority. Form 483 lists observations at close-out. Form 484 receipts any samples collected. The Establishment Inspection Report is the investigator's full internal record and is not issued to the firm at close-out.

Surveillance vs for-cause

A surveillance inspection is routine and risk-based, covering the facility broadly. A for-cause inspection is triggered by a specific concern and is typically narrower in scope but more intensive around the triggering issue.

Key regulations

FD&C Act Section 704 - FDA's statutory authority to inspect. 21 CFR Part 211 - current good manufacturing practice requirements being verified. FDA Investigations Operations Manual - the methodology FDA investigators follow during an inspection.